Metabolic Research Stack

About Metabolic Research Stack

What is the Metabolic Research Stack?
This bundle pairs Semaglutide and Tirzepatide — the two most clinically validated incretin receptor agonists — in a single kit with bacteriostatic water included. The pairing makes specific scientific sense: Semaglutide is a selective GLP-1 receptor agonist (single receptor), while Tirzepatide is a dual GIP/GLP-1 receptor agonist. Comparing their effects in the same experimental model is one of the more tractable ways to understand what GIP receptor co-activation adds to GLP-1R signaling alone.

Both compounds have extensive Phase III clinical trial programs — SUSTAIN/STEP for Semaglutide, SURPASS/SURMOUNT for Tirzepatide — which provides a rich clinical literature context for interpreting experimental findings. The SURMOUNT-1 data showing ~21% change in metabolic endpoints with Tirzepatide versus STEP-1's ~15% metabolic endpoint change with Semaglutide is exactly the kind of difference that researchers want to understand mechanistically. The bundle format is practical: both compounds, reconstitution water, ready to run parallel protocols without separate accessory orders.

Mechanism of Action

FAQ

What research questions can this bundle help answer?

The primary question is what GIP receptor co-activation adds to GLP-1R agonism alone. By running parallel experiments with Semaglutide (GLP-1R only) and Tirzepatide (GLP-1R + GIPR), you can isolate GIP-specific contributions to glucose regulation, lipid metabolism, metabolic endpoints, or any other parameter you're measuring. Secondary questions include dose-response comparisons, examining endpoints where the dual agonist shows differential effects (adipogenesis, pancreatic beta cell responses), and studying whether the two compounds interact differently with specific tissue types that express GIPR but not GLP-1R.

Which model systems are appropriate for these compounds?

Both compounds have been studied extensively in rodent models (diet-induced obesity mice, Zucker rats, db/db mice) where GLP-1R and GIPR expression is well-characterized. Cell-based systems including pancreatic beta cell lines (MIN6, INS-1), intestinal enteroendocrine cell models, and adipocyte differentiation assays are commonly used for mechanistic work. The literature provides extensive pharmacokinetic and pharmacodynamic data in mice and non-human primates that can inform dosing in preclinical studies. Standard GLP-1R and GIPR receptor binding assays are available for functional characterization.

Research Overview

Stack Components

Compound 1Semaglutide (GLP-1R selective agonist)
Compound 2Tirzepatide (GIP/GLP-1R dual agonist)
IncludedBacteriostatic water for reconstitution
Research useSingle vs. dual incretin agonist comparative studies

Storage
Store lyophilized peptides at -20°C. Reconstitute each with the included bacteriostatic water; stable at 4°C for up to 4 weeks after reconstitution. Keep separated in labeled vials to avoid mix-up.

Quality
HPLC purity analysis, mass spec identity confirmation, endotoxin testing on every batch. COA ships with every order. EU-based QC under CERTALAB S.R.L.

Product Specifications

• Purity: ≥98% (HPLC verified)
• Form: Lyophilized powder
• SKU: STACK-WL

Certificate of Analysis available for every batch. View COAs →

For research purposes only. Not for human consumption.